Research Overview

We have completed extensive preclinical work, Phase I safety and are readying NRP2945 for clinical Phase II studies. 

Clinical Studies Planned and Completed:

1. Clinical Phase II concept study in adults with typical absence epilepsy completed 2019.
2. Clinical Phase I study in healthy volunteers completed in 2017.
3. IND filing planned for 2022 for both LGS and drTLE.
4. Clinical Phase II in Lennox Gastaut Syndrome (LGS) children planned for 2023-2024.
5. Clinical Phase II in adults with drug resistant Temportal Lobe Epilepsy (drTLE) adults planned for 2022-2023. 

Preclinical Studies Planned and Completed :

• Hit and Lead selection with thalamocortical and cerebellar microexplant phenotypic assay screens (neuroprotection, neurogenesis, synaptogenesis).
• Preclinical model screening with NRP2945 for epilepsy, MS, ALS, peripheral neuropathy and ophthalmology mimicking animal models.
• In vitro ADME determination for NRP2945.
• Official preclinical development in in rat and dog GLP-tox/PK studies.
• Rat juvenile tox/Pk studies planned for IND filing in the US for start of pediatric Lennox-Gastaut therapeutic study with NRP2945.